- Home
- ACAD
as 02-21-2025 4:00pm EST
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Upcoming Earnings Alert:
Get ready for potential market movements as ACADIA Pharmaceuticals Inc. ACAD prepares to release earnings report on 26 Feb 2025.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.4B | IPO Year: | 2004 |
| Target Price: | $25.33 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.15 - $26.56 | Next Earning Date: | 02-26-2025 |
| Revenue: | $929,236,000 | Revenue Growth: | 47.06% |
| Revenue Growth (this year): | 36.88% | Revenue Growth (next year): | 8.01% |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
ACAD: Raising target price to $21.00
Business Wire
7 days ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
9 days ago
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
Business Wire
9 days ago
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
MT Newswires
11 days ago
Deutsche Bank Initiates Coverage on ACADIA Pharmaceuticals With Hold Rating, $22 Price Target
Simply Wall St.
16 days ago
High Growth Tech Stocks To Watch In February 2025
Argus Research
17 days ago
ACAD: Raising target price to $20.00
Argus Research
24 days ago
ACAD: What does Argus have to say about ACAD?
Compare ACAD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.